epidermal growth factor receptor p53 tumor suppressor gene STROCYTOMAS are the most common neoplasms of the central nervous system, comprising more than 60% of primary tumorsJ 9 They may be graded according to the World Health Organization (WHO) classification schemeJ 8 Glioblastomas multiforme (WHO Grade IV) are believed to arise either de novo or by progression from astrocytomas (WHO Grade II) or anaplastic astrocytomas (WHO Grade III). 29, 35 In contrast, pilocytic astrocytomas (WHO Grade I) rarely progress to a higher grade. 35,39,42,5: In general, progression of human cancers results from unique combinations of genetic alterations in proto-oncogenes and known or putative tumor suppressor genes.11,4~ For astrocytic tumors, the genetic alterations most often reported are mutation or alteration of the p53 tumor suppressor gene; 3' 4,7,12,13,21,2+-28,34,3v,41,46 loss of heterozygosity for chromosome 17p, 4,7,~~ 22, 25, 28, 37, 41, 44, 46 ,49 for chromosome 10~ 2,8,10,12,15,22,44,47,49+51 for chromosome 9p, ~6,22,31 or for chromosome 19q; 4s amplification and rearrangement of the epidermal growth factor receptor (EGFR) gene (c-erbB-2); 1, 5, 6, 14, 15, 22, 33, 44, 47, 49, 53, 54 amplification and rearrangement of the MDM2 gene; 33 and infrequent amplification of the oncogenes N-myc, c-myc, gli, N-ras, K-ras, and platelet-derived growth factor receptorA(PDGF-RA)J ,5,9,~7, 36, 43, 44, 50, 53 Most studies to date have analyzed one or two of these genetic events in Grade II to IV astrocytic tumors.
Studies that have analyzed three or more genetic events in the same tumor have been restricted largely to Grade III and IV astrocytomas. H~,~t,15`~'22`3~,37`~4-49,s3 These studies show that inactivation of the p53 gone occurs early through loss of one 17p allele and mutation in the other p53 allele, that losses of putative tumor suppressor genes on chromosomes 9p and 10 underlie the progression from anaplastic astrocytoma to glioblastoma, and that amplification of the EGFR gene is a relatively late event in glioblastoma multiforme formation. These findings imply that glioblastomas arise from low-grade tumors by the sequential development of these genetic changes. However, it is currently unclear whether some glioblastomas may arise de novo via other molecular pathways and whether such de novo tumors have a distinct profile of molecular genetic change s. n~,~ s ,4~
To further address the issue of genetic variants of glioblastomas multiforme, we have analyzed 65 astrocytic tumors, representing WHO Grades I to IV, for all three of the most common changes assessed in astrocytomas: loss of heterozygosity for chromosomes 17p and 10, and amplification of the EGFR gone. 15, 16, 22, 44, 49 Alterations of the p53 gene in these 65 astrocytomas have been reported previously. 7, 21, 27 In addition, we have assessed the oncogenes N-myc, c-myc, and N-ras for amplification or gene rearrangements in all 65 astrocytomas. Our results demonstrate that distinct combinations of genetic changes can serve to classify astrocytomas into different tumor variants. Based on these tumor variants, we hypothesize several different genetic pathways leading to glioblastoma multiforme.
Materials and Methods

Human Tumor Samples and Histological Analysis
Primary tumor samples from 55 patients and recurrent tumor samples from 10 patients were obtained during surgery (Table  l) . The astrocytomas included in this study consisted of seven pilocytic astrocytomas (Grade I), eight astrocytomas (Grade 11), 16 anaplastic astrocytomas (Grade fit), and 34 glioblastomas multiforme (Grade IV). Pieces of tumor tissue from each specimen were processed both for deoxyribonucleic acid (DNA) analysis and immunohistochemistry. For DNA analysis, samples were snap-frozen in liquid nitrogen and stored at -70~ For immunohistochemical study, samples were fixed in 10% formalin, processed routinely, embedded, and stored at room temperature until sectioning. All specimens were reviewed by a neuropathologist (D.C.M.) and graded according to the WHO classification system. ~8
DNA Extraction and Southern Blot Analysis
Partially thawed tumor pieces were Dounce homogenized in DNA extraction buffer containing 10 mM Tris-HC1 (pH 7.5), 150 rnM NaC1, and 2 mM ethylenediamine tetra-acetic acid (pH 8.0). The cell suspension was digested with proteinase K (200 /xg/ml) and sodium dodecyl sulfate (SDS, 0.5%) overnight at 37~ and the genomic DNA was extracted by salting out with 6 M NaC1. v Genomic DNA (10/xg) from tumor samples was digested to completion with the appropriate restriction endonuclease and separated by electrophoresis through 1.2% agarose gels. The DNA fragments were transferred to nylon membranes. .7 The DNA probes (100 ng) were radiolabeled with [c~-32p]-deoxycytidine triphosphate by random priming't and added to prehybridized filters in hybridization solution containing 50% formamide, 5 • standard saline citrate (SSC), 5 x Denhardt's solution, 0.1% SDS, 50 mM sodium phosphate (pH 7.2), and 250 ~g/ml denatured salmon sperm DNA at 42~ Filters were washed three times (200 rpm for 5 minutes) at room temperature in 2 • SSC/0.I% SDS and twice more at 60~ for 15 minutes in (). 1 • SSC/0.1% SDS. Filters were exposed to x-ray film with intensifying screens at -70~ for autoradiography.
DNA Probes and Restriction Endonucleases
Loss of heterozygosity for chromosome 17p was analyzed using two probes, pYNZ22 (D17S3G) and p144D6 (D17S34), following digestion of the DNA with the enzyme Hinfl. Loss of heterozygosity for chromosome 10 was analyzed using three probes after digestion of the DNA with one of three restriction endonucleases: probe TBQ7 (D10S28) with RsaI and MspI, probe TBQI4.16 (D10S33) with Rsal, and probe pEFD75 (D10S25) with RsaI. Probes TBQ7 and TBQ14.16 map to the p arm of chromosome 10, while pEFD75 maps to the q arm. Amplification of the EGFR gene was assessed using the probe pE7 following digestion with the enzyme EcoRI (see below). The probe pHM2A was used to assess the human c-mos locus. Amplification or rearrangements of the oncogenes N-myc, c-myc, and N-ras were assessed on EcoRI-digested DNA with the probes HP112 (N-myc), HPI32 (c-myc), and HP129 (N-ras).~
Analysis of EGFR Gene Amplification
To determine EGFR gone amplification, nylon membranes were first hybridized with the human c-erbB-specific probe pE7 (EGFR). The blots were stripped and then rehybridized with pHM2A (c-mos) to serve as a control for the signal intensity of a single-copy human gone within the same DNA sample. The optical density of a 3.7-kb EcoRI fragment of the EGFR gene was compared to the optical density of a 3.0-kb fragment of the c-mos gene using a laser densitometer; tissue from normal brain was available for comparison. The relative ratio of the optical density of the two hybridizing EcoRI fragments was calculated for each specimen. Values of 1.0 or less indicated no gene amplification, while values greater than 1.0 indicated gene amplification.
lmmunohistochemical Analysis of EGFR
A monoclonal antibody against the EGFR gone was used in this study.w Sections 6 /xm thick were cut from paraffinembedded tissue, collected onto poly-L-lysine-coated slides, dried, and stored at room temperature until use. Sections were deparaffinized and rehydrated prior to analysis. Endogenous peroxidase activity was eliminated by incubation with 0.3% hydrogen peroxide in 30 (PBS) for 15 minutes followed by three washes in PBS. To reduce nonspecific binding, the sections were incubated in 10% nonimmune rabbit serum for 30 minutes. Sections were covered with primary antibody at a predetermined optimum dilution (1:20 of the manufacturer's concentration was used) in 50 mM PBS with 1% bovine serum albumin and 0.5% normal goat serum, and incubated in a humidified chamber at 4~ overnight. A positive control tissue was included. Negative controls consisted of sections incubated with normal rabbit serum instead of the primary antibody. Sections were washed three times in PBS and incubated with biotinylated rabbit anti-mouse immunoglobulin G for 30 minutes at room temperature. The antigen-antibody complexes were visualized using the streptavidin-biotin complex immunoperoxidase method,H using 3,3'-diaminobenzidine tetrahydrochloride as the chromagen. Slides were counterstained with Delafield's hematoxylin and mounted
IIHistostain-SP streptavidin-biotin complex obtained from Zymed, San Francisco, California. in the standard fashion. Samples were coded and evaluated jointly (by F.F.L. and D.C.M.). Positive samples showed cytoplasmic or cell surface immunostaining.
Statistical Analysis
Differences between groups were assessed by Fisher's exact test. Table 1 presents the results of each genetic change assessed in 65 astrocytomas. Table 2 summarizes the  frequency of each genetic change for each tumor grade  and Table 3 the frequency of genetic changes in 65 astrocytomas in relation to p53 alterations.
Results
Analysis of Loss of Chromosome 17p
Loss of helerozygosity for chromosome 17p was assessed using the two highly polymorphic probes (Table 2 ). In contrast, loss of heterozygosity for chromosome 17p occurred in five (31%) of 16 anaplastic astrocytomas. The loss of heterozygosity for chromosome 17p in nine (26%) of 34 glioblastomas multiforme confirms previous findings. 7 The frequency of chromosome 17p loss in either anaplastic astrocytomas or glioblastomas compared to that of pilocytic astrocytomas and astrocytomas was significant (p < 0.05).
Analysis of Loss of Chromosome 10
Loss of heterozygosity for chromosome 10 was assessed using three polymorphic probes: two for 10p (TBQ7 and TBQ14.16) and one for 10q (pEFD75). A sample was scored positive for loss of heterozygosity for chromosome 10 when all three probes showed loss of alleles on chromosome 10. Figure 1 shows the pattern of loss for chromosome 10 alleles from representative glioblastomas (Fig. 1A) and lower-grade astrocytomas (Fig. 1B) using probe TBQ7. No pilocytic astrocytoma or astrocytoma, and only two (13%) of the 16 anaplastic astrocytomas exhibited loss of chromosome 10 (Table 2 ). However, 13 (38%) of the 34 glioblastomas showed loss of heterozygosity for chromosome 10. The frequency of chromosome 10 loss in glioblastomas compared to all the other grades was significant (p < 0.04).
Analysis of N-myc, c-myc, and N-ras Genes
Amplification and gene rearrangement for N-myc, c-myc, and N-ras were assessed for all 65 astrocytomas. Neither gene amplification nor rearrangements were found for any of these three oncogenes in any of the tumors (data not shown).
Analysis of EGFR Gene Amplification
Amplification of the EGFR gene was assessed in 52 tumor samples by Southern blot analysis; 20 samples were also assessed by immunohistochemistry. In 13 samples, only immunohistochemical studies were used to assess EGFR gene amplification. Figure 2A shows the EcoRI restriction patterns of the EGFR gene for representative glioblastomas and Fig. 2B shows the same blot rehybridized with a probe to c-mos. The signal intensity for a single-copy gene, c-mos, controlled for the amount of DNA loaded into each lane, and DNA from normal brain served as a control for the unamplified EGFR gene. A densitometric comparison of the relative signal intensity of the 3.0-kb EcoRI c-mos fragment with the 3.7-kb EcoRI EGFR fragment showed that the EGFR gene was amplified five to 15 times over that observed in normal brain ( Fig.  2A; samples 255, 278, and 336) . Three of these cases also showed rearrangements in the EGFR gene; two of these three are shown in Fig. 2A(samples 255 and 278) .
Of the 20 cases examined by both Southern blot analysis and immunohistochemical studies, all seven cases with EGFR gene amplification were immunopositive; all 13 cases without amplification were negative for EGFR protein expression. In addition, the 13 cases analyzed only by immunohistochemical techniques were negative for EGFR protein expression.
Overall, none of the seven pilocytic astrocytomas and eight astrocytomas demonstrated EGFR gene amplification (Table 2 ). Only one (6%) of the 16 anaplastic astrocytomas showed amplification compared with seven (21%) of the 34 glioblastomas.
Frequency of Genetic Changes in Relation to p53 Alterations
Alterations in the p53 gene have previously been documented in these 65 astrocytomas using the single- (Table 1) . Table 3 summarizes the frequency of loss of heterozygosity for chromosomes 17p and 10 as well as EGFR gene amplification in these two groups of tumors. Loss of heterozygosity for chromosome 17p occurred in 12 (28%) of 43 tumors with p53 alterations in contrast to two (9%) of 22 tumors without p53 alterations (p < 0.04). Loss of chromosome 10 occurred in 11 (26%) of 43 tumors with p53 alterations and in four (18%) of 22 tumors without p53 alterations. This difference was not significant. Amplification of the EGFR gene occurred in three (7%) of 43 tumors with p53 alterations in contrast to five (23%) of 22 tumors without p53 alterations (p < 0.03).
Genetic Variants of Astrocytic Tumors
To further characterize the formation of glioblastoma multiforme, individual tumor samples were analyzed for combinations of p53 alteration (defined as positive immunostaining for p53 protein in the presence or absence of p53 gene mutations), loss of heterozygosity for chromosomes 17p and 10, and amplification or rearrangements of the EGFR gene and the oncogenes N-myc, c-mye, and N-ras (Table 1 ). This analysis showed that astrocytic tumors could be divided into three variants.
One tumor variant consisted of the 43 tumors with p53 alterations. This variant was found in all grades of astrocytoma: five pilocytic astrocytomas, five astrocytomas, 10 anaplastic astrocytomas, and 23 glioblastomas. None of the pilocytic astrocytomas or astrocytomas with p53 alterations demonstrated any additional changes at any of the other genetic loci that were assessed. Of the 10 anaplastic astrocytomas, five showed p53 alterations only, four also showed loss of F~G. 2. Southern blot analysis of epidermal growth factor receptor (EGFR) gene amplification in glioblastomas. Representative tumor DNA was digested with EcoRI and the blots hybridized initially with the pE7 DNA probe to assess EGFR gene copy number. Sample "Norm" is DNA from normal brain for comparison of gene copy number. The blots were stripped and rehybridized with the probe pHM2A, which detects the single-copy c-mos locus. Arrows denote the 3.7-kb EcoRI fragment of the EGFR gene (A) and the 3.0-kb fragment of the c-mos gene (B). Amplification of the EGFR gene is shown in Samples 255, 278, and 336. Rearrangements of the EGFR gene are noted in Samples 255 and 278 with the presence of additional DNA fragments. Codes above the lanes refer to sample numbers listed in Table 1 . Norm = normal results. heterozygosity for chromosome 17p, and one also showed loss of heterozygosity for chromosome 10. Of the 23 glioblastomas, eight showed p53 alterations only, four also showed loss of chromosome 17p, four also showed loss of chromosome 10, and one also showed amplification of the EGFR gene. The third tumor variant(s) consisted of the 16 tumors with no change at any of the genetic loci examined. This group consisted of all grades of astrocytomas: two pilocytic astrocytomas, three astrocytomas, five ariaplastic astrocytomas, and six glioblastomas.
Discussion
Pathways of Glioblastoma Multiforme Formation
Glioblastomas multiforme may occur by progression from a low-grade astrocytoma, or alternatively appear to arise de novo without evidence of development from a low-grade tumor. The molecular analysis presented here demonstrates three or more genetic variants of astrocytomas, which support at least three pathways leading to the formation of glioblastoma multiforme ( progressive accumulation of genetic changes with increasing grades of malignancy, ~~ whereas the analysis of the tumor variant without p53 alterations (six samples) would support a model for de novo glioblastomas.16.49 The other tumor variant(s) (16 samples) showed no genetic changes among those assessed in this study; the molecular and genetic origins of these tumors have yet to be identified. Therefore, these glioblastomas multiforme may have arisen either from one or more unique pathways or from one of the two known pathways, that is, by progression or de novo.
Progression Pathway
In astrocytic tumors, p53 gene mutations have been documented with an overall frequency of 5% in pilocytic astrocytomas (one of 19), 26% in astrocytomas (eight of 31), 25% in anaplastic astrocytomas (13 of 51), and 39% in glioblastomas (39 of 100). 26 However, several recent reports have documented accumulation of the p53 protein in the absence of detectable p53 gene mutations in more than 60% of astrocytic tumors of all grades of malignancy. 21,24,27,34 Using a combination of DNA and protein analyses, p53 alterations were detected in 71% of pilocytic astrocytomas (five of seven), 63% of astrocytomas (10 of 16), 64% of anaplastic astrocytomas (18 of 28), and 65% of glioblastomas (31 of 48). 21'24'27'34 Therefore the frequency of p53 alterations, particularly in low-grade astroeytomas (WHO Grades I and II), is much higher than first supposed based solely on standard p53 gene-mutation analyses. Thus, p53 alterations play a significant role in the initiation of astrocytic tumor formation.
The p53 gene resides on the p arm of chromosome 17. Inactivation of the p53 gene occurs most commonly through the loss of one 17p allele with mutation in the remaining p53 allele. Although this study did not find loss of heterozygosity for chromosome 17p in Grade II astrocytomas (none of eight), loss of chromosome 17p has been reported for astrocytoma Grades II to I V . 4'7A0'I1'15 '22'28"37'44'46'49 The overall frequency of chromosome 17p loss in astrocytic tumors in these studies is 20% (six of 30) in astrocytomas, 36% (26 of 73) in anaplastic astrocytomas, and 28% (64 of 226) in glioblastomas. We, like others, found that a significant fraction of tumors show a loss of one 17p allele with a mutation in the remaining p53 allele. 4,7,25,28' 37' 46 This would result in complete inactivation of the p53 gene and altered p53 function. However, other tumors are characterized by the presence of a p53 gene mutation with no loss of 17p alleles. In this instance, normal p53 function may be altered by a mutation in one allele with retention of the other wild-type allele because of the so-called "dominant negative" effect, whereby the usual tetramerie structure of the p53 protein is disrupted by a mutation in one allele. 23,45 Therefore, inactivation of both alleles may not be necessary for disrupting normal p53 function.
Alteration of the p53 gone may also occur through amplification of the MDM2 gene? ~ The product of the MDM2 gone has been shown to regulate p53 protein activity by sequestering the wild-type protein. 3~ Amplification and overexpression of the MDM2 gene has been reported in 8% to 10% of anaplastic astrocytomas and glioblastomas? 3 No amplification or rearrangement of the MDM2 gene was found in the 65 astrocytic tumors analyzed in this study. 2m7 Therefore, MDM2 gone amplification and overexpression can account for aberrant p53 protein function in only a small fraction of astrocytic tumors. Genes similar to MDM2 that regulate the function or activity of p53 protein may be found to play a role in some astrocytic tumors.
Alteration of the p53 gene is an early event in astrocytic tumor progression and can occur through a variety of mechanisms as discussed above. Inactivation of p53 alters normal p53 function, resulting in deregulated cell growth and increased "genetic instability. ''2~ Therefore, low-grade astrocytomas with p53 alterations have a greater probability for further genetic aberrations, which could lead to progression to higher grades of malignancy. 2~
Loss of heterozygosity for chromosome 10 is one of the most frequently detected genetic abnormalities in astrocytic tumors, generally restricted to glioblastomas and with an overall frequency of 63% (137 of 219) in glioblastomas compared to 12% (eight of 68) 28 1011 15 22 44 47 4951 in anaplastic astrocytomas., . . . . . . . .
Loss of chromosome 10 has not been observed in pilocytic astrocytomas (none of 16) or in astrocytomas (none of 30) studied to date. The frequent loss of chromosome 10 in glioblastomas would suggest that the tumor suppressor gene(s) may play a role in progression to this tumor grade. The putative tumor suppressor gone(s) on chromosome 10 has not been identified. 32 Among astrocytic tumors, amplification of the EGFR gene is most frequently observed in glioblastomas. 1,5,6.14,15.22~33.44A7,4tk53. 54 The results of this study together with others show that the overall frequency of EGFR gene amplification is 0% (none of 24) in pilocytic astrocytomas, 5% (three of 57) in astrocytomas, 17% (13 of 78) in anaplastic astrocytomas, and 35% (112 of 319) in glioblastomas. Tumors demonstrating gene amplification have increased amounts of ribonucleic acid transcripts from the gene and immunohistochemically identifiable overexpression of the cell surface protein? '6 Many tumors with EGFR gene amplification also show rearrangements that occur following amplification? ,s Of eight cases in this study with amplified EGFR genes, three demonstrated gene rearrangements. Amplification of the EGFR gene was a rare event (three of 43) in tumors with p53 alteration. However, it appeared to be a late event generally associated with the loss of heterozygosity for chromosome 10.
In addition, other genetic changes not analyzed in this study, such as loss of heterozygosity for chromosomes 5, 6, 7, 9p, llp, 13q, 14q, 15q, 19q, and 22, may also plav a role in the formation of some glioblastomasY 1'fS'32,4s Therefore, progression from low-grade astrocytoma to glioblastoma multiforme may proceed along several alternative routes with different combinations of genetic changes, but all of them are predicated upon the genetic instability created by the accumulation of p53 protein. 21,24,26,33,3~ De Novo Pathway
In the de novo pathway, glioblastomas arise in the absence of p53 alterations. (This tumor variant most likely corresponds to the clinical group of glioblastomas that appear to arise de novo.) These tumors undergo genetic changes that directly result in the most malignant phenotype. Most tumors show amplification of the EGFR gene and some also show loss of heterozygosity for chromosome 10. I~ss of chromosome 17p in this group (two of six) occurred in the absence of both p53 mutation and p53 protein accumulation. These results strongly suggest that loss of tumor suppressor genes that have been postulated to reside on both chromosome 17p (distinct from the p53 gene) and chromosome 10 are important events in this variant of astrocytic tumors. 7'8'11 '15'36-3s'5~ Two recent studies have analyzed glioblastomas and anaplastic astrocytomas for similar genetic changes. a6, 49 James, et al., 16 analyzed 12 glioblastomas, eight anaplastic astrocytomas, and 10 astrocytomas for loss of chromosomes 9p, 17p, and 10 and amplification of the EGFR gene. Von Deimling, eta/., 49 assessed 67 glioblastomas for loss of chromosomes 17p and 10 and amplification of the EGFR gene. Unfortunately, neither study assessed the same tumors for p53 gone mutations or alterations. Despite these limitations, both studies identified a group of tumors characterized by loss of chromosome 10, EGFR gone amplification, and infrequent loss of chromosome 17p. However, von Deltaling, et al., used the presence or absence of chromosome 17p to divide glioblastomas into different genetic subtypes, "assuming" that there is a close association between the loss of one 17p allele and the presence of a p53 gene mutation in the remaining 17p allele. This assumption does not take into account data from a large number of reports which show that approximately 20% of astrocytomas with loss of one 17p allele do not contain a p53 gene mutation in the other 17p allele, a,7,12, 25.28.37.46 Therefore, some of the glioblastomas with loss of chromosome 17p, designated by yon Deimling, et aI., as glioblastoma multiforme Type 1, most likely belong to the group designated glioblastoma multiforme Type 2, which are similar to the de novo tumor variants without p53 alterations described here.
Most of the tumors believed to be clinical de novo glioblastomas are characterized either by loss of chromosome 10 alone, by amplification of the EGFR gene alone, by loss of chromosome 10 and amplification of the EGFR gene, or by loss of chromosome 17p in combination with loss of chromosome 9p or chromosome 10 or EGFR gene amplification. 16,49 Since the de novo tumor variant represents only 15% of the glioblastomas in this study (five of 34), additional analyses will be needed of glioblastomas without p53 alterations to confirm and extend the observations made here.
Alternative Pathways
Finally, 25% of the astrocytomas in this study (16 of 65) did not show any detectable change in any of the genetic loci assessed. These results imply that other proto-oncogenes and tumor suppressor genes may be critical in the pathway leading to the formation of the third tumor variant(s). Loss of putative tumor suppressor genes on the chromosomes noted above, as well as amplification of oncogenes such as PDGF-RA, gli, and genes not yet identified may underlie the formation of this third variant of astrocytic tumors. 5,15,~7, 32 Future analyses of multiple changes in individual tumors and of changes in tumors in individual patients will be necessary to completely understand the full spectrum of genetic changes and the timing of such changes in the formation of glioblastoma multiforme. Current studies are aimed at following the clinical outcome in patients with the three tumor variants we have identified. The molecular genetic classification of astrocytic tumors may lead to insights regarding prognosis and treatment.
